{"id":69871,"date":"2026-07-13T16:39:39","date_gmt":"2026-07-13T08:39:39","guid":{"rendered":"https:\/\/flcube.com\/?p=69871"},"modified":"2026-07-13T16:39:41","modified_gmt":"2026-07-13T08:39:41","slug":"teva-secures-global-rights-to-polpharma-biologics-ocrelizumab-biosimilar-expanding-multiple-sclerosis-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69871","title":{"rendered":"Teva Secures Global Rights to Polpharma Biologics&#8217; Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Teva Pharmaceutical Industries Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/TEVA:NYSE\">NYSE: TEVA<\/a>) and <strong>Polpharma Biologics<\/strong> announced a <strong>global licensing agreement<\/strong> granting Teva <strong>exclusive rights to commercialize both formulations<\/strong> of Polpharma Biologics&#8217; proposed <strong>biosimilar to ocrelizumab<\/strong>, upon regulatory approval.<\/p>\n\n\n\n<h2 id=\"h-deal-structure-amp-territory\" class=\"wp-block-heading\">Deal Structure &amp; Territory<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Teva Pharmaceutical Industries Ltd.; Polpharma Biologics<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Ocrelizumab biosimilar (intravenous and subcutaneous formulations)<\/td><\/tr><tr><td><strong>License Type<\/strong><\/td><td>Exclusive commercialization rights<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>United States, Europe, Brazil, Canada, Australia, New Zealand, Israel, Turkey<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>09 Jul 2026<\/td><\/tr><tr><td><strong>Development Status<\/strong><\/td><td>Under development by Polpharma Biologics<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">This strategic partnership leverages Teva&#8217;s extensive global commercial infrastructure with Polpharma Biologics&#8217; specialized biosimilar development expertise in one of the most valuable biologic franchises.<\/p>\n\n\n\n<h2 id=\"h-product-profile-amp-market-context\" class=\"wp-block-heading\">Product Profile &amp; Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reference Product:<\/strong> Ocrelizumab (Ocrevus\u00ae), developed by Roche&#8217;s Genentech<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Humanized monoclonal antibody targeting CD20-positive B cells<\/li>\n\n\n\n<li><strong>Indications:<\/strong> Relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS)<\/li>\n\n\n\n<li><strong>Market Size:<\/strong> Global ocrelizumab sales exceeded $5.6 billion in 2025<\/li>\n\n\n\n<li><strong>Patent Expiry:<\/strong> Key patents expire in major markets between 2026-2028<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Ocrelizumab represents one of the most successful multiple sclerosis therapies ever launched, making it a highly attractive target for biosimilar development. The availability of both intravenous and subcutaneous formulations addresses evolving patient and provider preferences for administration convenience.<\/p>\n\n\n\n<h2 id=\"h-strategic-partnership-dynamics\" class=\"wp-block-heading\">Strategic Partnership Dynamics<\/h2>\n\n\n\n<h3 id=\"h-polpharma-biologics-responsibilities\" class=\"wp-block-heading\">Polpharma Biologics Responsibilities<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Development:<\/strong> Full responsibility for clinical and regulatory development activities<\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> Complete control over manufacturing processes and supply chain<\/li>\n\n\n\n<li><strong>Technical Expertise:<\/strong> Leveraging proven biosimilar development platform<\/li>\n\n\n\n<li><strong>Quality Systems:<\/strong> Maintaining GMP-compliant manufacturing facilities<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-teva-responsibilities\" class=\"wp-block-heading\">Teva Responsibilities<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Submissions:<\/strong> Leading regulatory filing strategy in licensed territories<\/li>\n\n\n\n<li><strong>Commercialization:<\/strong> Full commercial responsibility upon approval<\/li>\n\n\n\n<li><strong>Market Access:<\/strong> Payer negotiations and reimbursement strategy<\/li>\n\n\n\n<li><strong>Distribution:<\/strong> Leveraging existing specialty pharmaceutical distribution network<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This division of responsibilities optimizes each partner&#8217;s core competencies while ensuring efficient development and commercial execution.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-competitive-landscape\" class=\"wp-block-heading\">Market Impact &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Current Market<\/th><th>Biosimilar Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>MS Treatment Cost<\/strong><\/td><td>High-cost biologic therapy ($70,000-$90,000 annually)<\/td><td>Significant cost reduction potential<\/td><\/tr><tr><td><strong>Patient Access<\/strong><\/td><td>Limited by high co-pays and formulary restrictions<\/td><td>Improved access through lower pricing<\/td><\/tr><tr><td><strong>Healthcare Systems<\/strong><\/td><td>Substantial budget impact on payers<\/td><td>Reduced burden on healthcare budgets<\/td><\/tr><tr><td><strong>Innovation Incentive<\/strong><\/td><td>Premium pricing supports R&amp;D investment<\/td><td>Balanced approach to innovation and access<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The introduction of ocrelizumab biosimilars is expected to generate substantial savings for healthcare systems while expanding treatment access for MS patients globally.<\/p>\n\n\n\n<h2 id=\"h-commercial-implications\" class=\"wp-block-heading\">Commercial Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Potential:<\/strong> Multi-billion dollar opportunity across licensed territories<\/li>\n\n\n\n<li><strong>Pricing Strategy:<\/strong> Expected 15-30% discount to reference product pricing<\/li>\n\n\n\n<li><strong>Market Share:<\/strong> Potential to capture significant share in competitive MS biosimilar market<\/li>\n\n\n\n<li><strong>Launch Timing:<\/strong> Dependent on regulatory approval timelines in key markets<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> First-mover advantage in certain territories possible<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Teva&#8217;s established presence in neurology and multiple sclerosis markets provides strong foundation for successful ocrelizumab biosimilar launch.<\/p>\n\n\n\n<h2 id=\"h-strategic-significance\" class=\"wp-block-heading\">Strategic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Enhancement:<\/strong> Strengthens Teva&#8217;s growing biosimilars portfolio in high-value therapeutic areas<\/li>\n\n\n\n<li><strong>Neurology Leadership:<\/strong> Reinforces Teva&#8217;s position as leading MS therapy provider<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> Extends Polpharma Biologics&#8217; reach beyond traditional European markets<\/li>\n\n\n\n<li><strong>Biosimilar Expertise:<\/strong> Validates Polpharma Biologics&#8217; capabilities in complex monoclonal antibody biosimilars<\/li>\n\n\n\n<li><strong>Healthcare Value:<\/strong> Supports broader mission of improving access to essential biologic therapies<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, commercial launches, and market expectations. Actual results may differ due to risks including regulatory decisions, competitive dynamics, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Polpharma Biologics announced a global licensing agreement granting&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[43,1072,4854,1071],"class_list":["post-69871","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biosimilars","tag-nyse-teva","tag-polpharma-biologics","tag-teva-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Teva Secures Global Rights to Polpharma Biologics&#039; Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Polpharma Biologics announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics&#039; proposed biosimilar to ocrelizumab, upon regulatory approval.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69871\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Teva Secures Global Rights to Polpharma Biologics&#039; Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio\" \/>\n<meta property=\"og:description\" content=\"Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Polpharma Biologics announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics&#039; proposed biosimilar to ocrelizumab, upon regulatory approval.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69871\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-13T08:39:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-13T08:39:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69871#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69871\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Teva Secures Global Rights to Polpharma Biologics&#8217; Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio\",\"datePublished\":\"2026-07-13T08:39:39+00:00\",\"dateModified\":\"2026-07-13T08:39:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69871\"},\"wordCount\":538,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biosimilars\",\"NYSE: TEVA\",\"Polpharma Biologics\",\"Teva Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69871#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69871\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69871\",\"name\":\"Teva Secures Global Rights to Polpharma Biologics' Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-13T08:39:39+00:00\",\"dateModified\":\"2026-07-13T08:39:41+00:00\",\"description\":\"Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Polpharma Biologics announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics' proposed biosimilar to ocrelizumab, upon regulatory approval.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69871#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69871\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69871#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Teva Secures Global Rights to Polpharma Biologics&#8217; Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Teva Secures Global Rights to Polpharma Biologics' Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio - Insight, China&#039;s Pharmaceutical Industry","description":"Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Polpharma Biologics announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics' proposed biosimilar to ocrelizumab, upon regulatory approval.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69871","og_locale":"en_US","og_type":"article","og_title":"Teva Secures Global Rights to Polpharma Biologics' Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio","og_description":"Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Polpharma Biologics announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics' proposed biosimilar to ocrelizumab, upon regulatory approval.","og_url":"https:\/\/flcube.com\/?p=69871","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-13T08:39:39+00:00","article_modified_time":"2026-07-13T08:39:41+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69871#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69871"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Teva Secures Global Rights to Polpharma Biologics&#8217; Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio","datePublished":"2026-07-13T08:39:39+00:00","dateModified":"2026-07-13T08:39:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69871"},"wordCount":538,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biosimilars","NYSE: TEVA","Polpharma Biologics","Teva Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69871#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69871","url":"https:\/\/flcube.com\/?p=69871","name":"Teva Secures Global Rights to Polpharma Biologics' Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-13T08:39:39+00:00","dateModified":"2026-07-13T08:39:41+00:00","description":"Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Polpharma Biologics announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics' proposed biosimilar to ocrelizumab, upon regulatory approval.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69871#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69871"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69871#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Teva Secures Global Rights to Polpharma Biologics&#8217; Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69871","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69871"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69871\/revisions"}],"predecessor-version":[{"id":69872,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69871\/revisions\/69872"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69871"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69871"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69871"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}